A recently published article in Forbes states that British biotech company GW Pharmaceuticals has announced positive results on its latest Phase 3 clinical trial for its drug Epidiolex. The cannabidiol-based drug is used to treat children with a rare form of childhood epilepsy called Lennox-Gastaut syndrome.
GW Pharmaceuticals has been noted to proclaim that they do not want this product to be confused with medical marijuana. Epidiolex is an oral pharmaceutical formulation of cannabidiol, or CBD, one of many cannabinoids found in the cannabis sativa plant. CBD is a non-psychoactive component of the cannabis plant.
This just adds more confusion about the governments rescheduling argument. The DEA can declare Epidiolex, cannabinoid drug a medicine, but then still insist marijuana has no medicinal benefits?